N-(benzo[d][1,3]dioxol-5-yl)-3-methyl-5-oxo-5H-thiazolo[3,2-a]pyrimidine-6-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: N-(benzo[d][1,3]dioxol-5-yl)-3-methyl-5-oxo-5H-thiazolo[3,2-a]pyrimidine-6-carboxamide
• 英文别名: N-(1,3-benzodioxol-5-yl)-3-methyl-5-oxo-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxamide
• 化学式: C₁₅H₁₁N₃O₄S
• mdl: MFCD04466977
• 分子量: 329.336
• InChiKey: VCNBIWDTYOHBJY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  106
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] THIAZOLO(3,2-A) PYRIMIDINONE AND OTHER HETEROBICYCLIC PYRIMIDINONE COMPOUNDS FOR USE IN MEDICAL THERAPY<br/>[FR] THIAZOLO(3,2-A)PYRIMIDINONE ET AUTRES COMPOSÉS HÉTÉROBICYCLIQUES DE PYRIMIDINONE POUR UTILISATION À DES FINS THÉRAPEUTIQUES
  申请人：LYSOSOMAL THERAPEUTICS INC

  公开号：WO2017040879A1

  公开（公告）日：2017-03-09

  The invention provides heterobicyclic pyrimidinone compounds such as thiazolo[3,2-a]pyrimidinone compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary heterobicyclic pyrimidinone compounds described herein include 5-oxo- 2,3-dihydro-5H-hiazolo[3,2-a]pyrimidine-6-carboxarnide compounds.

  该发明提供了异双环嘧啶酮化合物，例如噻唑并[3,2-a]嘧啶酮化合物，含有这种化合物的组合物，医疗工具包，以及使用这种化合物和组合物治疗医学疾病的方法，例如高雪氏病、帕金森病、路易体病、痴呆症或多系统萎缩症。本文描述的示例异双环嘧啶酮化合物包括5-氧代-2,3-二氢-5H-噻唑并[3,2-a]嘧啶-6-羧酰胺化合物。
• THIAZOLO[3,2-A] PYRIMIDINONE AND OTHER HETEROBICYCLIC PYRIMIDINONE COMPOUNDS FOR USE IN MEDICAL THERAPY
  申请人：Lysosomal Therapeutics Inc.

  公开号：US20190112316A1

  公开（公告）日：2019-04-18

  The invention provides heterobicyclic pyrimidinone compounds such as thiazolo[3,2-a]pyrimidinone compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary heterobicyclic pyrimidinone compounds described herein include 5-oxo-2,3-dihydro-5H-hiazolo[3,2-a]pyrimidine-6-carboxamide compounds.